Processa Pharmaceuticals (PCSA) vs PharmaCyte Biotech (PMCB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Oct 9, 2026.
Summary
PharmaCyte Biotech is the larger company by market cap ($4.3 million vs $3.8 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | PCSA | PMCB |
|---|---|---|
| Share price | $1.35 | $0.3974 |
| Market cap | $3.77M | $4.27M |
| 1-day change | -4.93% | -2.02% |
| EPS (TTM) | $-4.33 | $-2.31 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| 52-week high | $11.08 | $1.51 |
| 52-week low | $1.32 | $0.3339 |
| Distance from 52-week high | -87.81% | -73.68% |
| Average volume | 224.03K | 205.72K |
| Shares outstanding | 2.79M | 10.74M |
| Employees | 12 | 2 |
| Sector | Healthcare | Healthcare |
| Industry | Biotechnology | Biotechnology |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Processa Pharmaceuticals
PCSA stock →Processa Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, develops cancer therapy drugs to improve the safety and efficacy of cancer treatment in the United States. The company's drugs are modifications of existing FDA-approved oncology drugs, resulting in an alteration of the metabolism and/or distribution of drugs while maintaining the existing mechanisms for killing cancer cells.
Healthcare · Biotechnology · 12 employees
About PharmaCyte Biotech
PMCB stock →PharmaCyte Biotech, Inc., a biotechnology company, focused on developing and preparing to commercialize cellular therapies for cancer using live cell encapsulation technology in the United States. The company's cellular therapies are developed based on Cell-in-a-Box, a proprietary cellulose-based live cell encapsulation technology used as a platform to treat various types of cancer.
Healthcare · Biotechnology · 2 employees
PCSA vs PMCB FAQ
Which is bigger, Processa Pharmaceuticals or PharmaCyte Biotech?
PharmaCyte Biotech (PMCB) is larger, with a market capitalization of $4.27M compared with $3.77M for Processa Pharmaceuticals (PCSA).
Are Processa Pharmaceuticals and PharmaCyte Biotech in the same industry?
Yes. Both are classified in the Biotechnology industry within the Healthcare sector.